AFSOS-SFRO-SFH-SFNEP-SFCE-GFRP guidelines on radio-induced nausea and vomiting
- PMID: 36223807
- DOI: 10.1016/j.critrevonc.2022.103825
AFSOS-SFRO-SFH-SFNEP-SFCE-GFRP guidelines on radio-induced nausea and vomiting
Abstract
Introduction: The prevalence of radiation-induced nausea and vomiting varies between 40% and 80%. They have many consequences on treatment and comorbidities. This work thus aimed to define clinical practice guidelines for the management of radiation-induced nausea and vomiting.
Methods: XXXXX, XXXX, XXX, XXXXX, XXXX and XXXX compiled a working group who draft these recommendations.
Results: The assessment of the emetogenic risk found two main predictive factors: 1) the irradiated anatomical location, 2) an associated concomitant chemotherapy. In the case of exclusive radiotherapy, primary antiemetic prophylaxis depends on the emetogenic risk (the irradiated anatomical location). In the case of concomitant chemotherapy, the emetogenic risk is generally higher and the primary antiemetic prophylaxis corresponds to that of chemotherapy-induced nausea and vomiting. In cases where symptoms persist, remedial treatments are poorly codified.
Conclusion: Radiation-induced nausea and vomiting remains underdiagnosed and undertreated, its rapid detection and treatment are essential to reinstate good clinical practice.
Keywords: Nausea; Prevention; Radiotherapy; Supportive care; Treatment; Vomiting.
Copyright © 2022 Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest None.
Similar articles
-
[Update of guidelines of the AFSOS, SFRO, SFH, SFNCM, SFCE, GFRP for the management of radio-induced nausea and vomiting].Bull Cancer. 2024 Nov;111(11):1065-1076. doi: 10.1016/j.bulcan.2024.08.015. Epub 2024 Oct 9. Bull Cancer. 2024. PMID: 39384523 French.
-
A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.J Oncol Pharm Pract. 2013 Jun;19(2):138-44. doi: 10.1177/1078155212457966. Epub 2012 Oct 3. J Oncol Pharm Pract. 2013. PMID: 23034405
-
[Chemotherapy induced-vomiting--a practical guide for prevention and therapy].Dtsch Med Wochenschr. 2006 Aug 25;131(34-35):1869-72. doi: 10.1055/s-2006-949172. Dtsch Med Wochenschr. 2006. PMID: 16915549 Review. German.
-
Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.J Oncol Pharm Pract. 2020 Dec;26(8):1964-1969. doi: 10.1177/1078155220938847. Epub 2020 Jul 6. J Oncol Pharm Pract. 2020. PMID: 32633661
-
Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines.Support Care Cancer. 2005 Feb;13(2):122-8. doi: 10.1007/s00520-004-0705-3. Epub 2004 Dec 8. Support Care Cancer. 2005. PMID: 15592688 Review.
Cited by
-
Brain radiotherapy and dorsal vagal complex irradiation: A new organ at risk to decrease radiation-induced nausea and vomiting?Clin Transl Radiat Oncol. 2024 Dec 15;51:100902. doi: 10.1016/j.ctro.2024.100902. eCollection 2025 Mar. Clin Transl Radiat Oncol. 2024. PMID: 39811541 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources